French immuno-oncology company Innate Pharma (Euronext: IPH) has announced the resignation of chief executive Mondher Mahjoubi.
Formerly oncology head at AstraZeneca (LSE: AZN), Dr Mahjoubi joined Innate in 2017, and will now move on to pursue: “a senior level opportunity at a large pharmaceutical company,” the firm said.
Co-founder and former CEO Hervé Brailly will take over at Innate on an interim basis, while a permanent successor is sought.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze